Table 1 Baseline characteristics and evolution of clinical parameters throughout the study period
Baseline characteristics | Evolution of clinical parameters | |||||
|---|---|---|---|---|---|---|
Baseline valueΦ | Visit 1Φ | Visit 2Φ | Visit 3Φ | F = , p = * | ||
Male: female | 10/18 (56): 8/18 (44) | N | 18 | 17 | 15 | |
Age (years) | 29.5 ± 20.5 | ppFEV1 | 73.6 ± 25.6 | 73.3 ± 30.5 | 71.5 ± 35.1 | 2.27, 0.12 |
∆F508 homozygous | 6 (33) | ppFVC | 87.9 ± 14.2 | 86.2 ± 19.6 | 86.4 ± 23.6 | 0.76, 0.48 |
∆F508 heterozygous | 8 (44) | BMI (kg/m2) | 22.0 ± 2.5 | 22.0 ± 2.6 | 22.4 ± 3.0 | 1.01, 0.36 |
Mutation others | 4 (22) | FFM (kg) | 42∇ ± 16.7 | 43.5∇ ± 16.7 | 50.2∇ ± 19.0 | 3.49, 0.05 |
VO2peak (ml/min/kg) | 28.7◊ ± 10.4 | 31.5◊ ± 9.0 | 27.9◊ ± 9.4 | 0.24, 0.79 | ||
Pancreatic insufficiency | 17 (94) | Φ N (%) or Median ± IQR * ANOVA with repeated measures ∇ Visit 1&2 N = 17, Visit 3 N = 12 ◊ Visit 1 N = 17, Visit 2 N = 15, Visit 3 N = 11 | ||||
CF-related diabetes | 7 (39) | |||||
CF-related liver disease | 9 (56) | |||||